Comprehensive Psychiatry
Volume 48, Issue 5 , Pages 395-399, September 2007

The prevalence and correlates of psychiatric comorbidity in individuals with complicated grief

  • Naomi M. Simon

      Affiliations

    • Massachusetts General Hospital and Harvard Medical School
    • Corresponding Author InformationCorresponding author. Tel.: +1 617 726 7913; fax: +1 617 643 3080.
  • ,
  • Katherine M. Shear

      Affiliations

    • Columbia University School of Social Work
  • ,
  • Elizabeth H. Thompson

      Affiliations

    • Massachusetts General Hospital and Harvard Medical School
  • ,
  • Alyson K. Zalta

      Affiliations

    • Massachusetts General Hospital and Harvard Medical School
  • ,
  • Carol Perlman

      Affiliations

    • Massachusetts General Hospital and Harvard Medical School
  • ,
  • Charles F. Reynolds

      Affiliations

    • University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic
  • ,
  • Ellen Frank

      Affiliations

    • University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic
  • ,
  • Nadine M. Melhem

      Affiliations

    • University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic
  • ,
  • Russell Silowash

      Affiliations

    • University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic

published online 05 July 2007.

Abstract 

Background

Complicated grief (CG), variously called pathological or traumatic grief, is a debilitating syndrome that is not currently included in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) nomenclature. One issue that remains under debate is whether this condition can be clearly distinguished from other psychiatric disorders, such as major depression and posttraumatic stress disorder, with which CG frequently coexists.

Methods

Using a structured clinical interview for CG and the Structured Clinical Interview for DSM-IV, trained experienced raters conducted careful diagnostic assessments of individuals seeking treatment of bereavement-related distress. All study participants met criteria for a current CG syndrome. Liberal criteria were used to diagnose DSM-IV disorders, making no attempt to decide if symptoms could be explained by grief.

Results

Of 206 who met the criteria for CG, 25% had no evidence of a current DSM-IV Axis I disorder. When present, psychiatric comorbidity was associated with significantly greater severity of grief; however, even after adjustment for the presence of comorbidity, severity of CG symptoms was associated with greater work and social impairment.

Limitations

It is likely that our study underestimated the rate of CG without comorbidity because fewer DSM diagnoses would have been made if a judgment about grief had been taken into consideration.

Conclusions

Our data provide further support for the need to identify CG as a psychiatric disorder.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Naomi Simon is a consultant for Paramount Biosciences and is on the Speaker's Bureau for Continuing Medical Education and other presentations for Forest Laboratories, Janssen, Lilly, Pfizer, Sepracor and UCB Pharma. Dr Simon has participated in clinical trials sponsored by Cephalon, Janssen, UCB Pharma, and Sepracor. Dr Simon has received investigator-initiated grants from AstraZeneca, Cephalon, Forest Laboratories, GlaxoSmithKline, Pfizer, Lilly, the National Institute of Mental Health, and the National Alliance for Research of Schizophrenia and Depression. Katherine Shear is a consultant for Pfizer and receives research grant funding from Forest Laboratories. Charles Reynolds III receives research support in the form of pharmaceutical supplies for National Institutes of Health–sponsored work from GlaxoSmithKline, Forest, Pfizer, Lilly, and Bristol-Myers Squibb. Ellen Frank is a consultant for Pfizer, Eli Lilly, and Novartis. Dr Frank receives grant support from the National Institute of Mental Health and the Forest Research Institute and serves on the advisory board for Pfizer, Eli Lilly, and Servier. Nadine Melhem has received a travel award from the American Foundation for Suicide Prevention. All other authors declare that they have no conflicts of interest.

PII: S0010-440X(07)00058-2

doi:10.1016/j.comppsych.2007.05.002

Comprehensive Psychiatry
Volume 48, Issue 5 , Pages 395-399, September 2007